×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVDL – avadel pharmaceuticals plc - ordinary share (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVDL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/3
08:51 am
avdl
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 [Yahoo! Finance]
Low
Report
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 [Yahoo! Finance]
1/3
08:00 am
avdl
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
Low
Report
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
12/12
05:22 am
avdl
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock [Yahoo! Finance]
Low
Report
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock [Yahoo! Finance]
12/11
08:08 am
avdl
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy [Yahoo! Finance]
Medium
Report
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy [Yahoo! Finance]
12/11
08:00 am
avdl
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
Medium
Report
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
11/27
06:47 am
avdl
Narcolepsy Treatment Market 2024 to 2034 Projected to Reach USD 8,718.3 Million by 2034 with 5.1% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Narcolepsy Treatment Market 2024 to 2034 Projected to Reach USD 8,718.3 Million by 2034 with 5.1% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
11/26
10:15 am
avdl
Sleep Consortium Announces the Illuminate Hypersomnia Adjunct Scientific Meeting to Tackle Drug Development Challenges for Idiopathic Hypersomnia [Yahoo! Finance]
Low
Report
Sleep Consortium Announces the Illuminate Hypersomnia Adjunct Scientific Meeting to Tackle Drug Development Challenges for Idiopathic Hypersomnia [Yahoo! Finance]
11/18
12:33 pm
avdl
State-of-the-science webinar will explore narcolepsy and hypersomnia
Low
Report
State-of-the-science webinar will explore narcolepsy and hypersomnia
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
07:00 am
avdl
avadel pharmaceuticals plc - ordinary share
BEAT
Report
-18.1%
avadel pharmaceuticals plc - ordinary share
8/8/2024
07:00 am
avdl
avadel pharmaceuticals plc - ordinary share
BEAT
Report
-1.6%
avadel pharmaceuticals plc - ordinary share
5/8/2024
07:00 am
avdl
avadel pharmaceuticals plc - ordinary share
MISS
Report
-10.6%
avadel pharmaceuticals plc - ordinary share
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/27
04:15 pm
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 24 Filed by: Palczuk Linda
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 24 Filed by: Palczuk Linda
12/19
04:21 pm
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 17 Filed by: Palczuk Linda
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 17 Filed by: Palczuk Linda
12/16
07:00 am
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 13 Filed by: MCHUGH THOMAS S
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 13 Filed by: MCHUGH THOMAS S
12/12
07:00 am
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 11 Filed by: MCHUGH THOMAS S
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 11 Filed by: MCHUGH THOMAS S
12/10
06:15 pm
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 06 Filed by: Divis Gregory J
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 06 Filed by: Divis Gregory J
12/10
06:14 pm
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 10 Filed by: Glass Geoffrey Michael
Medium
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 10 Filed by: Glass Geoffrey Michael
12/10
07:00 am
avdl
Form 4 AVADEL PHARMACEUTICALS For: Dec 06 Filed by: Palczuk Linda
Low
Report
Form 4 AVADEL PHARMACEUTICALS For: Dec 06 Filed by: Palczuk Linda
12/3
06:04 am
avdl
Form 8-K AVADEL PHARMACEUTICALS For: Dec 02
High
Report
Form 8-K AVADEL PHARMACEUTICALS For: Dec 02
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/21
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
32.0%
6/13 Form 8-K AVADEL PHARMACEUTICALS For: Jun 13 20.4%
6/5 Form 8-K AVADEL PHARMACEUTICALS For: May 30 20.0%
3/24 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.75 price target on the stock. 18.2%
9/23 Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019 17.6%
6/10 Form 8-K AVADEL PHARMACEUTICALS For: Jun 04 17.0%
5/24 Form 4 AVADEL PHARMACEUTICALS For: May 22 Filed by: Ende Eric J 15.5%
9/17 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th 15.4%
11/19 Form 4 AVADEL PHARMACEUTICALS For: Nov 15 Filed by: Ende Eric J 14.3%
4/27 Form DEF 14A AVADEL PHARMACEUTICALS For: Aug 05 13.4%
6/13 Form 8-K AVADEL PHARMACEUTICALS For: Jun 13 20.4%
6/5 Form 8-K AVADEL PHARMACEUTICALS For: May 30 20.0%
3/24 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.75 price target on the stock. 18.2%
9/23 Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019 17.6%
6/10 Form 8-K AVADEL PHARMACEUTICALS For: Jun 04 17.0%
5/24 Form 4 AVADEL PHARMACEUTICALS For: May 22 Filed by: Ende Eric J 15.5%
9/17 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th 15.4%
11/19 Form 4 AVADEL PHARMACEUTICALS For: Nov 15 Filed by: Ende Eric J 14.3%
4/27 Form DEF 14A AVADEL PHARMACEUTICALS For: Aug 05 13.4%
TOP News Decliners
3/12
Q4/2019 12/31/2019 EPS -0.070 ZacksConsensus -0.250 ActVsEst 0.180 - Beat
-20.7%
4/27 Form 8-K AVADEL PHARMACEUTICALS For: Apr 27 -14.9%
4/28 Avadel Pharmaceuticals Announces Pricing of Public Offering -12.1%
8/8 Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019 -11.4%
7/2 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -9.8%
6/3 Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer -8.8%
9/25 Form 8-K AVADEL PHARMACEUTICALS For: Sep 25 -8.7%
11/12 Form 8-K AVADEL PHARMACEUTICALS For: Nov 12 -8.3%
10/2 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.0%
8/30 Fresenius Kabi Introduces Phenylephrine Hydrochloride Injection, USP -7.4%
4/27 Form 8-K AVADEL PHARMACEUTICALS For: Apr 27 -14.9%
4/28 Avadel Pharmaceuticals Announces Pricing of Public Offering -12.1%
8/8 Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019 -11.4%
7/2 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -9.8%
6/3 Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer -8.8%
9/25 Form 8-K AVADEL PHARMACEUTICALS For: Sep 25 -8.7%
11/12 Form 8-K AVADEL PHARMACEUTICALS For: Nov 12 -8.3%
10/2 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.0%
8/30 Fresenius Kabi Introduces Phenylephrine Hydrochloride Injection, USP -7.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: